COMPASS THERAPEUTICS INCCMPX
ASignal's systematic analysis rates CMPX as Neutral.
Reflects the latest available analysis · analyzed Oct 4, 2026
The case on CMPX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong cash position with $179.88M in total cash
- Low debt-to-equity ratio of 0.06x indicating minimal leverage risk
- High liquidity with current ratio of 11.22x and quick ratio of 11.15x
- RSI at 5.63 indicating deeply oversold conditions, potential for reversal
- Negative return on equity (-56.66%) and return on assets (-33.03%)
- Negative operating cash flow ($-56.11M) and free cash flow ($-31.36M)
- MACD below signal line and negative histogram indicating bearish momentum
- Price significantly below 20-day and 50-day moving averages (SMA20: 1.5857, SMA50: 1.9722)
- Only one news source (ChartMill) and no Reddit mentions indicating minimal market interest
See the full verdict on CMPX
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes CMPX
Most investors never get a second opinion, let alone several. ASignal runs CMPX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.